Drug
RG7388 clinical trials
Also written Idasanutlin, RO5503781 and RG7388.
- studies test it
- 15
- open now
- 0
- in phase 3
- 1
- first study started
- 2011
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
15 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 5
Hoffmann-La Roche (10) · Mayo Clinic (1) · University Hospital Heidelberg (1) · John Mascarenhas (1) · Vanderbilt-Ingram Cancer Center (1) · St. Jude Children's Research Hospital (1)
Often tested with
Tested in the same studies.
Atezolizumab (2) · Cobimetinib (2) · Dexamethasone (1) · Ixazomib (1) · APG101 (1) · Alectinib (1) · HhAntag691 (1) · Temsirolimus (1)
Studies
Open first, then newest update. How each study uses RG7388 is read from its arms, and is right about nine times in ten.
Testing it · 15
- Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedPhase 1/2Mayo ClinicNCT02633059Written as Idasanutlin
- Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid TumorsWithdrawnPhase 1St. Jude Children's Research HospitalNCT05952687Written as Idasanutlin
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedPhase 1/2Hoffmann-La RocheNCT03555149Written as Idasanutlin
- NCT Neuro Master Match - N²M² (NOA-20)CompletedPhase 1/2University Hospital HeidelbergNCT03158389Written as Idasanutlin
- A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedPhase 3Hoffmann-La RocheNCT02545283Written as Idasanutlin
- A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyCompletedPhase 1Hoffmann-La RocheNCT02670044Written as Idasanutlin
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia VeraTerminatedPhase 2Hoffmann-La RocheNCT03287245Written as Idasanutlin
- Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerTerminatedPhase 1/2Vanderbilt-Ingram Cancer CenterNCT03566485Written as Idasanutlin
- A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) ParticipantsTerminatedPhase 1/2Hoffmann-La RocheNCT02624986Written as Idasanutlin
- Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaCompletedPhase 1John MascarenhasNCT02407080Written as RG7388
- A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT03362723Written as Idasanutlin
- A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)CompletedPhase 1Hoffmann-La RocheNCT02828930Written as Idasanutlin
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous LeukemiaCompletedPhase 1Hoffmann-La RocheNCT01773408Written as RO5503781 MBP
- A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except LeukemiaCompletedPhase 1Hoffmann-La RocheNCT01462175Written as RO5503781
- A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT01901172Written as RO5503781
Given in every arm · 3 — RG7388 is usual care beside what is tested
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsTerminatedPhase 1/2Hoffmann-La RocheNCT04029688Written as Idasanutlin
- A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete RemissionTerminatedPhase 1/2Hoffmann-La RocheNCT03850535Written as Idasanutlin
- A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedPhase 1/2Hoffmann-La RocheNCT03135262Written as Idasanutlin